Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT
Arcutis Biotherapeutics — Q2 2026 Earnings Presentation
17 slides from Arcutis Biotherapeutics's earnings presentation, Aug 5, 2026
Slide 1: 2nd Quarter 2026 Financial Results
2 Quarter 2026 nd Financial Results August 5, 2026
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation and the accompanying oral presentation contain manufacturing capabilities and strategy; current and future the accompanying oral presentation are made pursuant to the forward-looking statements within the meaning of Section 27A of agreements with third parties in
Slide 3: Today's Speakers
Today’s Speakers Frank Watanabe Patrick Burnett, Latha Vairavan President & CEO MD, PhD, FAAD Chief Financial Officer Chief Medical Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 3
Slide 4: Speakers & Agenda: Business Review
Speakers & Agenda Business Review Frank Watanabe President & CEO ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 4
Slide 5: Our Strategy to Sustain Near- and Long-term Growth
Our Strategy to Sustain Near- and Long-term Growth Grow current Expand ZORYVE Build our pipeline ZORYVE business into new markets • Received FDA approval of • Fully enrolled Ph 2 vitiligo • Continue to enroll Ph ZORYVE® (roflumilast) POC trial 1a/1b trial for ARQ-234 cream 0.3% in pediatric • Contin
Slide 6: Speakers & Agenda: Commercial Update
Speakers & Agenda Commercial Update Frank Watanabe President & CEO ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 6
Slide 7: Strong Net Product Revenues in Q2 2026
Strong Net Product Revenues in Q2 2026 Net Product Revenues $M • Q2‘26 net product revenues of 127.5 129.9 $129.9M, +59% vs. prior year 105.4 ‐ +23% net product revenues 99.2 quarter over quarter • GTN stable in the 50s • Expect quarter-over-quarter net sales growth in Q3 ’26 driven by patient deman
Slide 8: Sustained TRx Growth for ZORYVE Portfolio
Sustained TRx Growth for ZORYVE Portfolio – Reaching ~23,000 Weekly TRx (Rolling 4-Week Basis) 25,000 22,500 20,000 Foam 0.3% TRx Growth 17,500 (SebD) Launch R4 WEEK WEEKLY TRx 15,000 Cream 0.15% (AD) Launch vs. Q1’26 vs. Q2’25 12,500 Cream 0.05% (AD) Launch 10,000 Foam 0.3% (PsO) Launch Q2’26 +14%
Slide 9: Patient Access is Our Next Domain for Innovation
Patient Access is Our Next Domain for Innovation Virtual Health AI Enabled Patient Access Support A more convenient and flexible way to engage Leverages existing office workflow tool to with care streamline prescription fulfillment ZORYVE is a uniquely positioned product Customized AI platforms to s
Slide 10: Three Commercial Pillars to Drive ZORYVE Sales Inflection
Three Commercial Pillars to Drive ZORYVE Sales Inflection ZORYVE Growth Commercial DTC Patient Infrastructure Efforts Access Derm sales force Tori Spelling and Virtual health expansion and Max Homa leading platform and AI initiation of PCP Free to Be Me enabled fulfillment sales team campaign to bui
Slide 11: Speakers & Agenda: R&D Update
Speakers & Agenda R&D Update Patrick Burnett, MD, PhD, FAAD Chief Medical Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 11
Slide 12: Breadth of Clinical Activity is Setting the Foundation for Long-term ZORYVE Growth
Breadth of Clinical Activity is Setting the Foundation for Long-term, Sustainable ZORYVE Growth Breadth of Clinical Activity is Setting the Foundation for Long-term, Sustainable ZORYVE Growth Grow current ZORYVE business Expand ZORYVE into new markets Build our pipeline Q1 2026 Q4 2026 Q1 2026 Topli
Slide 13: ZORYVE has the Profile to Displace Topical Corticosteroids
ZORYVE Life Cycle Management ZORYVE has the Profile to Displace Topical Corticosteroids Efficacious and Fast Acting Broad MOA Safety and Tolerability Duration and Location of Use TCS ZORYVE Current clinical development activity demonstrates breadth of potential ZORYVE applications Graphic above for
Slide 14: Speakers & Agenda: Financial Results
Speakers & Agenda Financial Results Latha Vairavan Chief Financial Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 14
Slide 15: Q2 2026 Financial Results
Q2 2026 Financial Results GAAP Reported $ Millions, Except Per Share Amounts Q2 2026 Q2 2025 YoY Change Q1 2026 QoQ Change Product Revenues, Net 129.9 81.5 48.4 105.4 24.5 Other Revenues 0.0 0.0 0.0 0.0 0.0 Total Revenues 129.9 81.5 48.4 105.4 24.5 Cost of Sales 10.9 7.5 3.4 9.8 1.2 R&D Expense 20.4
Slide 16: Positive Cash Flow Generation from ZORYVE Franchise Allows for Investment to Sustain Growth
Positive Cash Flow Generation from ZORYVE Franchise Allows for Investment to Sustain Growth 2026 Guidance Capital Allocation Balance Sheet Strength Product Sales of Reinvest ZORYVE $239M Q2’26 Cash Balance* $525M-$540M Proceeds in Franchise $102M Long-term Debt, Net Sustained Positive Continue to in
Slide 17: Q&A
Q&A Frank Watanabe Patrick Burnett, Latha Vairavan President & CEO MD, PhD, FAAD Chief Financial Chief Medical Officer Officer ©Copyright 2026. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 17
Arcutis Biotherapeutics — Q2 2026 Earnings Presentation on 6ix